Experimental intervention: Insertion of Extracorporal Membrane Oxygenation (ECMO) within 24 hours of referral to an Intensive Care Unit. Control intervention: Insertion of Extracorporal Membrane Oxygenation (ECMO) as rescue therapy following failure of conventional therapy for ARDS. This conventional therapy will be standardized to reduce bias. Duration of intervention per patient: varies, depending on severity of pulmonary compromise Follow-up per patient: Until hospital discharge Accompanying measures: Serum Samples and bronchoscopy samples of patients included into the trial for secondary analysis of inflammatory parameters and potential biomarkers
The severe form of COVID-19 infection is characterized and marked by severe pneumonia and the
Acute Respiratory Distress Syndrome (ARDS). ARDS is characterized by the loss of pulmonary
tissue compliance and severe hypoxia. The central pathophysiologic changes of COVID-19+ ARDS
are dysregulated inflammation within the alveolar space and altered permeability of the
alveolar-capillary barrier. The public health impact of this COVID-19+ ARDS is considerable
with a large number of ARDS cases that need to be treated currently on German Intensive Care
Units. To date, the associated mortality ranges between 30 to 50%. In the ongoing COVID-19
crisis cases of ARDS will still increase and pose a significant challenge to the German
Medical System. Despite the emerging understanding of COVID-19+ ARDS, treatment only remains
to be symptomatic using mechanical ventilation, prone positioning and in severe cases of
hypoxia extracorporal membrane oxygenation (ECMO). Current evidence generated by clinical
trials demonstrates that patients with ARDS should be referred to a specialized center to
receive expert treatment. The use of ECMO might have a beneficial effect on overall patient
outcome, yet this has not been proven by clinical trials and to date ECMO is recommended as
measure of last resort in the current ARDS treatment guidelines. The timing of ECMO placement
to relieve hypoxia is an important question for the treating clinician but is not well
studied to date. This might also have impact on the long-term functional outcome of patients.
In addition, evidence about the role of ECMO in the outcome of COVID-19+ patients might have
significant impact on the referral of patients to a specialized center and is important for
the treating physician. Therefore, the investigators want to pursue the questions whether
early ECMO placement is superior than the placement of ECMO as a rescue measure, and whether
this could result in improved overall outcome of patients with COVID-19+ ARDS.
Procedure: ECMO Implantation
Insertion of Extracorporal Membrane Oxygenation (ECMO) within 24 hours of referral to an Intensive Care Unit.
Inclusion Criteria:
- COVID-19positive(+) ARDS as defined according to the Berlin Definition
- ratio of partial pressure arterial oxygen and fraction of inspired oxygen (PaO2/ FiO2)
≤100
- Bilateral opacities consistent with pulmonary edema on frontal chest radiograph
- requirement for positive pressure ventilation via an endotracheal tube or non-invasive
ventilation
- no clinical evidence of left atrial hypertension, or if measured, a Pulmonary Arterial
Wedge Pressure (PAOP) less than or equal to 18 mmHg.
- ≤ 7 days from the initiation of mechanical ventilation at the time of randomization. -
Patients must be enrolled within 96 hours of onset of ARDS -
Exclusion Criteria:
- COVID-19negative(-) ARDS
- Age less than 18 years
- More than 7 days since initiation of mechanical ventilation
- more than 96 hours since meeting ARDS criteria
- patient, surrogate or physician not committed to full intensive care support.
- pregnancy
University Hospital Tuebingen
Tuebingen, Germany
Peter Rosenberger, Prof., Principal Investigator
+4970712986622